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1.

Introduction

Prior to conducting large scale conﬁrmatory, or phase III, clinical trials it is common for researchers to
ﬁrst conduct phase I and II exploratory trials concerned with toxicology and pharmacology. Although
these preliminary trials are generally not adequately powered to prove eﬃcacy or non-inferiority, important
information regarding potential treatment beneﬁts can often be gleamed before proceeding to a larger trial.
Figure 1 displays survival curves resembling those observed during a recent phase II trial considering the
potential eﬃcacy of a new cancer chemotherapy treatment on all-cause mortality. In this phase II trial,
researchers observed that the experimental treatment being considered yielded a nonproportional hazards
eﬀect on survival, generally characterized by a delayed eﬀect on the hazard. Study sponsors hypothesized that
this delay in the separation of hazards may have been attributed to several factors, including the need for a
minimum time required for the treatment to show an eﬀect within patients or because there may exist a subset
of the sickest patients for which the occurrence of an event is inevitable regardless of treatment assignment.
Given the observed treatment eﬀect over mid to late followup times, it was agreed by the sponsors that it
would be appropriate to proceed to a larger conﬁrmatory trial investigating the eﬃcacy of the experimental
treatment. The statistical process involved in bringing this study to fruition involved three main steps:
(1) choosing a test statistic that would be likely to capture alternatives from the null hypothesis of equal
survival that were felt most scientiﬁcally relevant and plausible; (2) constructing alternatives that might
reasonably arise in a future study in order to evaluate the performance of the proposed test statistic; and
(3) choosing a group sequential stopping rule that would allow for early stopping in the event that suﬃcient
conﬁdence in favor of a decision for eﬃcacy or futility of the treatment were observed. It was recognized by
the study designers that, at least some, focus on the previously observed phase II data would be necessary to
suggest appropriate probability models for data which might be obtained during the conﬁrmatory trial and
to evaluate the adequacy of potential stopping rules used to monitor accruing data. In this manuscript we
report our approach to the statistical design of the proposed trial and provide one framework for designing
and evaluating group sequential survival studies when pilot data suggest alternatives which deviate from the
usual proportional hazards assumption.
Early in the design process, it was agreed by the study sponsors and trial designers that some form of a
weighted logrank statistic, highlighting treatment eﬀects occurring during mid to late followup, would be a
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Figure 1: Kaplan-Meier estimates of survival curves resembling those observed in a phase II trial considering
an experimental treatment for cancer on all cause mortality.

reasonable choice for use in the conﬁrmatory trial. The Gρ,γ class of weighted logrank statistics as deﬁned
by Fleming and Harrington (1991) is given by
ρ,γ

G


=

N1 + N0
N1 N0

1/2 



wj λ̂1j − λ̂0j ,

(1)

j∈F

where Ni denotes the initial sample size of group i, i = 0, 1, F denotes the set of distinct observed failure times
in the pooled sample, w(t) is deﬁned as {(n1t n0t )/(n1t + n0t )} Ŝ(t−)ρ [1 − Ŝ(t−)]γ , nit denotes the number
of persons at risk in group i at time t, Ŝ(t−) denotes the Kaplan-Meier estimate of the pooled sample just
prior to time t, λ̂i (t) ≡ dit /nit denotes the estimated hazard for group i at time t, and dit represents the
number of deaths observed in group i at time t. Thus, the Gρ,γ statistic represents a sum, over all failure
times, of weighted diﬀerences in the estimated hazards. Based upon the available pilot data, trial designers
concluded that the G1,1 statistic, which places increased weight to hazard diﬀerences estimated near the
median survival time of the pooled groups, would be provide a functional of the survival distributions that
would eﬃciently detect delayed treatment eﬀect alternatives taking the general form of those observed in
the phase II data.
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In designing the phase III trial, it was deemed ethically necessary that a group sequential analysis plan be
implemented to monitor data and stop the trial as soon as suﬃcient conﬁdence in favor of eﬃcacy or futility
was obtained. The use of group sequential methodology has become widespread in the conduct of clinic
trials. Many authors have addressed the design (Pocock, 1977; O’Brien and Fleming, 1979; Whitehead and
Stratton, 1983; Wang and Tsiatis, 1987; Emerson and Fleming, 1989), implementation (Lan and DeMets,
1983, Burington and Emerson, 2003), and analysis (Whitehead, 1986; Emerson and Fleming, 1990) of group
sequential trials. In particular, the body of group sequential methodology is well-deﬁned for situations in
which the within-individual treatment eﬀect is constant with respect to time. Common statistical techniques
that have been developed in this setting include the comparison of means of continuous data, proportions
or odds resulting from binomial data, and proportional hazards from censored time to event data. In
comparison, little attention has been devoted to the development of group sequential methods for monitoring
a treatment eﬀect which may vary with time, as the pilot data in Figure 1 suggest.
In order to ensure desirable operating characteristics of the group sequential design ultimately selected
for use in the phase III trial, a comprehensive evaluation of multiple stopping rules was necessary. Emerson
et al. (2004b) describe a variety of frequentist design characteristics which might be examined in the most
commonly encountered statistical problems. Among them are

1. The scientiﬁc measures of treatment eﬀect which will correspond to early termination for futility and/or
eﬃcacy.
2. The sample size requirements as described by the maximal sample size and summary measures of the
sample size distribution (e.g., mean, 75th percentile) as a function of the hypothesized treatment eﬀect.
3. The probability that the trial would continue to each analysis as a function of the hypothesized treatment eﬀect.
4. The frequentist power to reject the null hypothesis as a function of the hypothesized treatment eﬀect,
with the type I error corresponding to the power under the null hypothesis.
5. The frequentist inference (adjusted point estimates, conﬁdence intervals, and P values) which would
be reported were the trial to stop with results corresponding exactly to a boundary.
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Although these operating characteristics are relatively straightforward to evaluate in the setting of a timeinvariant treatment eﬀect, as described by Emerson et al. (2004b), they have not been fully addressed in
longitudinal situations where the observed treatment eﬀect within individuals may vary over the course of
follow-up.
In order to evaluate power curves, sample size distributions, and futility of continuing the trial, it is
necessary to construct alternatives at which these operating characteristics are to be estimated. Because our
choice of test statistic, G1,1 , does not necessarily correspond to a parameter of clinical interest, characterizing
meaningful alternatives from the null hypothesis can be diﬃcult. Further, in order to fully address the
scientiﬁc question of interest it is generally preferred to present stopping boundaries based upon a statistic
which represents some clinically meaningful measure of treatment eﬃcacy. This logic no longer holds when
using the nonparametric G1,1 statistic since this statistic does not correspond to a speciﬁc parameter of
interest. Hence care must be taken when considering potential stopping rules in order to examine what
point estimates for clinically meaningful measures arise upon study termination.
In the remainder of the manuscript we describe the procedure used for evaluating and selecting a group
sequential stopping rule to be applied to the phase III conﬁrmatory study. In order to evaluate the operating
characteristics of these designs, it was ﬁrst necessary to construct alternatives which were deemed plausible
in the conﬁrmatory trial given the prior information available regarding a nonproportional hazards treatment
eﬀect. Section 2 introduces a bootstrapping procedure used to simulate potential hypothesis testing alternatives using the observed pilot data displayed in Figure 1. In Section 3, we introduce the four candidate
stopping boundaries that were originally considered in the design evaluation process. Section 4 presents
simulation results illustrative of an approach used to choose between the candidate rules deﬁned in Section
3. Finally, Section 5 concludes with a discussion of the diﬀerences and challenges that arise when evaluating
group sequential stopping rules where early evidence indicates that the treatment eﬀect of interest may vary
with time.
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2.

Construction of hypothesis alternatives using observed pilot data

Frequentist operating characteristics are based on the sampling distribution of test statistics under various
alternative hypotheses. Hence, the deﬁnition of alternatives which should be considered when investigating
the operating characteristics of potential stopping rules is an essential component to the evaluation of group
sequential procedures. When parametric and semiparametric models are to be evaluated, the speciﬁcation
of alternatives is trivial since they are generally deﬁned by a particular parameter of interest (eg. the
hazard ratio in the case of the proportional hazards model). However, in a nonparametric setting, no such
parameterization exists and alternatives from the null hypothesis are no longer clearly deﬁned. In this
section we consider the use of the pilot data presented in Figure 1 to simulate potential alternatives at which
candidate design operating characteristics are to be evaluated.
In general, the deﬁnition of alternatives can be based on such necessary information as patient enrollment
rates, treatment eﬀects over time, and the survival experience and censoring distribution for each comparison
group as derived from pilot data. We propose the simulation of alternatives by resampling repeatedly
from the single set of observed Kaplan-Meier estimates of survival obtained from the phase II trial, ﬁrst
considering the null survival distribution from which alternatives should deviate. In deciding upon a null
survival distribution, one can draw on the statistical questions raised by the available pilot data. That is,
the question posed by the pilot data is whether any observed diﬀerences might reasonably be obtained by
drawing two samples from a single population. Such spurious diﬀerences might arise, for example, when
the combined samples were representative of a true null distribution, but randomization into two treatment
groups produced large separation between survival curves. Alternatively, it might be the case that the control
group is representative of the true null distribution, but that random sampling led to a treatment group with
better survival than expected. Under the ﬁrst scenario, we might choose the null survival distribution to be a
50-50 mixture of the estimated survival experience of the control and treatment samples from the pilot study,
while under the second scenario we might use estimates of the survival experience from the control sample
alone. Other scientiﬁcally reasonable options for the null survival distribution exist, including oversampling
healthier or sicker patients which may account for possible changes in eligibility criteria.
Given the existence of pilot data, one natural alternative to the chosen null distribution is the observed
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survival experience of the comparison group. However, one must also consider a variety of plausible alternatives when evaluating the operating characteristics of a statistical test. To construct a range of alternatives
we consider mixtures of the control and comparison Kaplan-Meier estimates of survival from the pilot data.
For example if the null survival distribution is taken to be that of the control sample then we may consider
‘mixing in’ the survival experience of the comparison sample in order to obtain various alternatives. Thus
0% mixing would be indicative of no treatment eﬀect on survival, 50% mixing would indicate a treatment
eﬀect in which the survival experience of the treated group represents a 50-50 mixture of the control and
comparison survival experience from the available pilot data, and 100% mixing would correspond to a treatment eﬀect that results in a survival experience that is equivalent to that of the comparison sample in the
pilot study. Letting (t1i , t2i , ..., tni i ) denote the ni observed failure times in treatment group i, i = 0, 1, the
construction of a single sample of size N from an alternative deﬁned by mixing parameter m would proceed
as follows:

1. Compute the Kaplan-Meier estimate of the survival distribution for the control and treatment groups
in the pilot study, Ŝ0 and Ŝ1 , respectively.
2. Deﬁne the alternative via the percentage that the control and treatment groups are to be mixed,
0 ≤ m ≤ 1.
3. For i = 0, 1 do
(a) Let Ni = round(N ∗ |(1 − i) − m|).
(b) Sample Ni survival times ti = (t∗1 , t∗2 , ..., t∗Ni ) with replacement from (t1i , t2i , ..., tni i , ∞) with
probability (1 − Ŝi (t1i ), Ŝi (t1i ) − Ŝi (t2i ), ...., Ŝi (tni i ) − 0).
(c) For j = 1, ..., Ni , if t∗j = ∞ set δj = 0, otherwise set δj = 1.
4. Combine the sampled survival times t = (t0 , t1 ) and event indicators δ = (δ0 , δ1 ).

Of course, the creation of alternatives need not be restricted simply to mixing survival experiences from
the pilot study. Another option is to construct alternatives by oversampling the healthiest patients from
the pilot study in order to represent various treatment eﬀects. In this setting, the alternative might be
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quantiﬁed by the weighting assigned to the healthiest patients. One advantage to this approach is that it
does allow for alternatives which correspond to greater eﬀects than seen in the pilot data. To deﬁne similar
alternatives when using the mixing approach described above, one could potentially use a combination of
both mixing and oversampling healthy patients (with or without possible semiparametric extensions based
on proportional hazards or accelerated failure time models), to consider alternatives which correspond to
greater diﬀerences than were observed in the pilot data.
In this case study, we deﬁne the null survival distribution to be the Kaplan-Meier estimate of the control
survival distribution depicted in Figure 1 and consider alternatives which are deﬁned in terms of mixtures
of the survival experience of the previously observed comparison sample. Speciﬁcally, when constructing
alternatives we will consider 0%, 20%, 40%, 60%, 80%, and 100% mixtures, where 0% mixing corresponds to
the control population from the original pilot data, and 100% mixing corresponds to the treated population
from the original pilot data.

3.

Introduction of candidate stopping rules

In deﬁning stopping boundaries we use the uniﬁed design family as proposed by Kittelson and Emerson
(1999). This particular design family encompasses all previously reported classes of group sequential designs,
including the Wang and Tsiatis (1987) family of boundary shape functions and the class of triangular tests
as proposed by Whitehead and Stratton (1983). Brieﬂy, the uniﬁed family utilizes three parameters: the
P -parameter which controls the curvature of the stopping boundary (larger values of P make early stopping
more diﬃcult), the R-parameter which allows for even greater ﬂexibility of the curvature of boundaries
(larger values of R make early stopping easier), and the A-parameter for which choices of A with small
absolute value make stopping at early analyses more diﬃcult.
In this and the following section, we will consider the operating characteristics of four group sequential
designs. We assume that the maximal number of accrued patients is 1000 (N =500 per treatment arm)
uniformly accrued to the study over a period of 3 years and each design is constructed to allow for 4 interim
analyses taking place at 12 months, 18 months, when 51% of subjects have experienced an event, and when
650 subjects have experienced an event. In selecting candidate designs, one-sided symmetric designs with
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early stopping under the null hypothesis were considered, however we note that equivalent stopping rules for
any one-sided test could have been created using a two-sided framework in the full parameterization of the
uniﬁed family. Also considered in the design selection process was the degree of early conservatism displayed
by candidate stopping rules. Due to our focus on late diﬀerences in survival, the majority of the proposed
group sequential designs evaluated in the current manuscript are highly conservative with respect to early
stopping in favor of futility (since the particular trial of interest would be required to carry on in order to
witness any treatment eﬀect), but not so conservative that they fail to protect against harm.
Ultimately, in addition to a reference ﬁxed sample design with one test occurring at 650 events, four
one-sided designs were chosen, with varying degrees of conservatism early on. The deﬁnitions of chosen
group sequential designs are as follows:

• DSN 1: A one-sided level .025 Pocock (1977) stopping rule (corresponding to P = .5, R = 0, and
A = 0) on both the lower (eﬃcacy) and upper (futility) boundaries. This design is constant on the
Z-statistic scale (See Figure 3(a)) and is generally regarded as being quite anti-conservative at early
analyses.
• DSN 2: A one-sided level .025 test utilizing the O’Brien and Fleming (1979) stopping rule (corresponding to P = 1, R = 0, and A = 0) on both the lower (eﬃcacy) and upper (futility) boundaries; See
Figure 3(b). Although this particular design is generally regarded as being highly conservative in early
analyses, in the setting of late diverging hazards it still may not yield the amount of conservatism
required early on.
• DSN 3: A one-sided level .025 test parameterized using the Wang and Tsiatis (1987) family of shape
functions. The stopping rule for this particular design has an O’Brien-Fleming lower (eﬃcacy) boundary corresponding to P = 1.0, R = 0, and A = 0, and an upper (futility) boundary corresponding to
P = 1.5, R = 0, and A = 0, which is extremely conservative at early analyses; See Figure 3(c).
• DSN 4: A one-sided level .025 test parameterized using the full ﬂexibility of the uniﬁed design family.
The lower (eﬃcacy) boundary takes P = 1.2, R = 0, and A = 0 (more conservative than the O’BrienFleming stopping rule), while the upper (futility) boundary takes P = 0, R = 0.5, and A = 0.3; See
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Figure 3(d). DSN 4 was chosen to increase the degree of conservatism of the previous designs on the
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Figure 2: Proposed group sequential stopping rules. Boundaries are plotted on the Z-statistic scale, assuming
equally spaced analysis times.
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4.

Evaluation of candidate stopping rules

In this section, we consider the evaluation of those group sequential designs deﬁned in Section 3 when
alternatives are constructed from the nonproportional hazards pilot data depicted in Figure 1(b). As noted
earlier, all evaluations are based upon the G1,1 weighted logrank test statistic, the test statistic chosen by
the study sponsor to best capture the general hypothesized alternative. In a manner analogous to Emerson
et al. (2004b), the presented evaluation focuses on a variety operating characteristics, including stopping
probabilities under various alternatives, power curves, sample size distributions, and measures of inference
on the decision boundaries.

4.1 Stopping probabilities
Due to ethical and economic concerns, clinical trial researchers are often concerned with the likelihood
of stopping a trial early due to high conﬁdence in favor of eﬃcacy, futility, or harm. To address this,
simulated stopping probabilities by treatment eﬀect, deﬁned in terms of the percent mixing as described in
Section 2, for each of the previously described group sequential stopping rules are presented in Figure 4.
Stopping probabilities were estimated by repeatedly sampling from the pilot data depicted in Figure 1(b)
under various levels of mixing, then counting the number of simulations that were stopped at each analysis
time. Presented estimates are based upon 5000 simulations performed at each alternative. In each plot,
the numbered contours represent the cumulative probability of stopping at the analysis time given by the
number on the contour. In addition, the vertical length encompassed by light colored regions between two
numbered contours reﬂects the probability of stopping in favor of eﬃcacy at the latter analysis time, while
the vertical length encompassed by dark regions between two contours indicates the estimated probability
of stopping in favor of futility at the latter analysis time.
Figure 4(a) displays stopping probabilities for the Pocock design. Under the null hypothesis of 0% mixing,
the probability of stopping in favor of eﬃcacy was estimated to be 1.10%, .60%, .90%, and .025% at the
ﬁrst, second, third, and fourth analyses, respectively, resulting in an estimated type I error rate of 2.85%.
Under the full alternative of 100% mixing, the probability of stopping in favor of eﬃcacy was estimated to
be 1.40%, 3.05%, 35.40%, and 9.95% at the ﬁrst, second, third, and fourth analyses, respectively, resulting
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Figure 3: Simulated stopping probabilities when selected group sequential designs are applied to alternatives
constructed from the nonproportional hazards pilot data depicted in Figure 1(b).

in an overall power of 49.80% at the 100% mixing alternative. Of particular interest is the high stopping
probabilities in favor of futility at early analyses under the full alternative when the Pocock boundary was
applied in this setting of late diverging hazards.
Estimated stopping probabilities for the O’Brien-Fleming design are displayed in Figure 4(b). We can
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see that the contour lines representing the ﬁrst two analysis times are nearly horizontal at zero for any
treatment eﬀect, indicating that there is little to no chance of early stopping in either direction at either of
these analyses when the O’Brien-Fleming design is invoked. Under the null hypothesis, the probability of
stopping in favor of treatment was estimated to be 0 at the ﬁrst two analyses, 0.95% at the third analysis
and 1.10% at the fourth and ﬁnal analysis, resulting in an overall type I error of 2.05%. Under an alternative
of 100% mixing, the probability of stopping in favor of eﬃcacy was estimated to be 47.70% at the third
analysis and 28.85% at the ﬁnal analysis, resulting in an overall power of 76.55%.
Due to the extreme early conservatism of DSN 3, no trials were stopped at the ﬁrst two analyses (see
Figure 4(c)). Under 100% mixing, the probability of stopping in favor of eﬃcacy at the third analysis when
using the DSN 3 stopping rule was estimated to be 47.30%, while the probability of stopping for eﬃcacy at
the ﬁnal analysis was estimated to be 29.80%.
Finally, in Figure 4(d) we can see that although no simulations stopped in favor of eﬃcacy at the ﬁrst or
second analysis, there does exist a reasonable chance of stopping early in favor futility at these early analyses
when DSN 4 was invoked. The probability of stopping early in favor of futility under the null hypothesis
was estimated to be 8.85% at the ﬁrst analysis, 2.00% at the second analysis, 5.55% at the third analysis,
and 81.40% at the ﬁnal analysis, implying that the estimated type I error for the design was 2.20%. Under
a treatment eﬀect of 100% mixing, the probability of stopping early in favor of eﬃcacy was estimated to be
zero at the ﬁrst two analyses, 40.00% at the third analysis and 33.30% at the ﬁnal analysis, resulting in an
estimated power of 73.30%.

4.2 Statistical power
From a statistical perspective, it is clearly of great interest to examine the power curve associated with
a given testing procedure. To complement the stopping probabilities displayed in Figure 5, plots of power
and relative power as a function of treatment for each of the considered designs are provided in Figure 6.
From Figure 6(a) we can see that great diﬀerences in the power curves were not found when comparing the
ﬁxed sample design, DSN 2, DSN 3, and DSN 4, however the DSN 1 (Pocock) design obtained substantially
lower power than any of the other four designs considered. We note that this loss in power is attributed
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to the rather anti-conservative Pocock futility boundary, allowing many trials to stop early before the late
occurring treatment eﬀect had been observed. Figure 6(b) better reﬂects decreases in power due to using a
group sequential design over a ﬁxed sample design with the same maximal sample size. The general trend
of the plot suggests that as treatment eﬀect increases, larger disparities in power are witnessed between the
ﬁxed sample test and the considered group sequential designs. Under the full alternative, DSN 2 obtained
1.75% lower power when compared to the ﬁxed sample test, DSN 3 suﬀered a decrease of 1.20% power
relative to the ﬁxed sample design, and DSN 4 revealed a 5.00% drop in power compared to the ﬁxed sample
design. As mentioned above, under an alternative of 100% mixing DSN 1 yielded the largest disparity in
power relative to the ﬁxed sample test, with an estimated drop of 28.5%.

4.3 Sample size distribution
Noting that in the group sequential setting the sample size is random, one should also consider the sample
size distribution before deciding upon a stopping rule. Figures 5(c) and 5(d) yield plots of the average number
of patients and the average number of events required by treatment eﬀect for each of the considered designs.
The average number of patients at each alternative was estimated by repeatedly simulating 5000 survival
curves under the respective alternative and applying each stopping rule to the simulated data. This process
yielded an estimate of the sample size for each simulation, allowing the number of patients required for each
sample to be averaged over the total number of simulations. In Figure 5(c), we can see that little to no
diﬀerence in the average number of required patients is found when comparing the 1000 accrued patients
required by the ﬁxed sample design to DSN 2 and DSN 3, regardless of the alternative considered. However,
there is a decrease in the average number of patients required when either DSN 1 or DSN 4 are invoked.
Under the null hypothesis, the average number of accrued patients was estimated to be 744 for DSN 1, and
932 for DSN 4. Hence we see eﬃciency gains, relative to the ﬁxed sample test, for the loss of power noted
in Figures 5(a) and 5(b).
The average number of events required by each design was also evaluated. Figure 5(d) displays the
average number of required events by treatment eﬀect. Here we can see that all of the group sequential
designs considered require (on average) fewer than the 650 events planned for the ﬁxed sample test, regardless
of treatment eﬀect. Under the null hypothesis of 0% mixing, the average required number of events was
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Figure 4: Estimated power curves (Figures (a) and (b)) and sample size distributions (Figures (c) and (d)
when selected group sequential designs are applied to alternatives constructed from the nonproportional
hazards pilot data depicted in Figure 1(b). Figure 5(b) represents power relative to the ﬁxed sample design.
Figure 5(c) and 5(d) display the average number of patients and average number of events by treatment
eﬀect, respectively.

estimated to be 323 for the Pocock design (DSN 1), 529 for the O’Brien-Fleming design (DSN 2), 549 for
DSN 3, and 579 for DSN 4. This ordering of the average number of events by design is nearly the same
throughout all treatment eﬀects, with exception to the number of events required by DSN 4 relative to DSN 2
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and DSN 3. In this case, as the treatment eﬀect began to grow, the average number of events required by
DSN 4 fell at a quicker rate than either DSN 2 or DSN 3. At the full alternative of 100% mixing, the
expected number of events was estimated to be 401 for DSN 1, 570 for DSN 2, 579 for DSN 3, and 554 for
DSN 4.

4.4 Inference on the boundary
Finally, to examine clinical measures of treatment eﬀect which correspond to boundary decisions, the
right-hand column of Table 1 yields minimal (for eﬃcacy) and maximal (for futility) estimates of treatment
eﬀect encountered when the O’Brien-Fleming (DSN 2) and DSN 4 stopping rules were applied to the range
of alternatives from 0% to 100% mixing. For this particular case study we present estimates corresponding
to the Cox estimate of the hazard ratio and a trimmed hazard ratio considering only the inner 50% of the
observed data. Again, estimates are based upon a total of 5000 simulated trials at each alternative. At the
ﬁrst analysis, we can see that no trials were stopped under the one-sided O’Brien-Fleming boundary, while
stoppage only occurred in favor of futility under DSN 4. In this case, the hazard ratio of 0.963 implies that
it is plausible, under the DSN 4 stopping rule, that a study could be stopped early in favor of futility when
testing is based upon the G1,1 statistic, despite the data showing a 4.7% overall decrease in the hazard.
At the second analysis time, none of the simulated trials were stopped in favor of eﬃcacy using either the
O’Brien-Fleming stopping rule or the DSN 4 stopping rule, while early stoppage in favor of futility occurred
at the second analysis under both designs. With respect to the O’Brien-Fleming design, the hazard ratio
of 1.278 implies that of all simulated trials stopped early for futility, the maximal treatment eﬀect observed
suggested a 27.8% increase in the hazard associated with treatment. The hazard ratio of 1.079 observed
under DSN 4 suggests that a 7.9% increase in the hazard associated with treatment was required for any of
the simulated studies to be stopped early in favor of futility at the second analysis time.
At the third interim analysis, trials were stopped early in favor of both eﬃcacy and futility for each of
the considered designs. The hazard ratio of 0.946 observed under DSN 2 suggests that it is plausible that a
study could be stopped early in favor of eﬃcacy despite the data showing only a 5.4% overall decrease in the
hazard. With respect to futility, the hazard ratio of 0.842 implies that at least one trial stopped early for
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Table 1: Minimal (for eﬃcacy) and maximal (for futility) estimates of treatment eﬀect by analysis time
when testing is based upon the G1,1 statistic. Alternatives were constructed using the pilot data depicted
in Figure 1. Hazard ratios represent the hazard of the treatment group relative to the control group.
Summary
Statistic

DSN1 (Pocock)
Eﬃcacy
Futility

DSN2 (OBF)
Eﬃcacy
Futility

Eﬃcacy

DSN3

DSN4

Futility

Eﬃcacy

Futility

5.524
–
–

-10.824
–
–

1.344
0.963
−∞

2.434
1.278
1.367

-5.783
–
–

1.883
1.079
1.134

-2.355
0.946
0.926

-1.019
0.842
0.759

-2.500
0.924
0.902

1.394
1.013
1.032

-1.993
0.958
0.944

-1.993
0.808
0.724

-1.979
0.970
0.944

-1.979
0.808
0.724

Time 1
Z statistic
Hazard Ratio
Trimmed HR

-7.362
–
–

Z statistic
Hazard Ratio
Trimmed HR

-4.825
–
–

6.285
–
–

-12.306
–
–

1.293
0.643
−∞

-6.810
–
–

1.823
0.961
0.877

-6.708
–
–
Time 2

3.180
1.770
1.826

-4.287
–
–
Time 3

Z statistic
Hazard Ratio
Trimmed HR

-2.388
0.908
0.914

-0.933
0.803
0.754

-2.545
0.888
0.877

1.583
1.058
1.115
Time 4

Z statistic
Haz Ratio
Trimmed HR

-1.991
0.924
0.911

-1.991
0.759
0.722

-1.973
0.924
0.922

-1.973
0.759
0.722

futility at the third analysis even though the data revealed a 15.7% overall decrease in the hazard associated
with treatment. Similar results for the eﬃcacy boundary were also observed under DSN 4 at the third and
ﬁnal analyses, though DSN 4 was found to be much more conservative with respect to stopping in favor of
futility at the third analysis when compared to the O’Brien-Fleming stopping rule.

5.

Discussion

The use of group sequential methodology has become widespread in the conduct of clinic trials. Because each
clinical trial presents unique scientiﬁc and statistical issues it is important to carefully evaluate candidate
group sequential designs to ensure desirable operating characteristics. Although this methodology is welldeﬁned for situations in which the within-individual treatment eﬀect is constant with respect to time (see
for example Emerson et al. (2004b)), when prior evidence for time-varying treatment eﬀects is present the
evaluation of potential designs is not a trivial task and this problem is made more complicated when testing
is based upon a nonparametric statistic.
In order to evaluate power curves, sample size distributions, and measures of futility, one must specify
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the alternatives at which test statistics are to be computed. When parametric and semiparametric models
are to be evaluated, the speciﬁcation of alternatives is trivial since they are generally deﬁned by a particular
parameter of interest (eg. the hazard ratio in the case of the proportional hazards model). However,
under nonproportional hazards when no parametric model is to be assumed, alternatives from the null
hypothesis are no longer clearly deﬁned. We have proposed a procedure for the simulation of hypothesis
testing alternatives that does not require the assumption of a parametric model by using observed pilot data.
Speciﬁcally, we propose that potential alternatives could be constructed by considering various mixtures of
the estimated survival experience observed in the pilot data or by oversampling healthier or sicker patients.
Ultimately, upon simulating alternatives one is able to estimate commonly examined operating characteristics
such as power curves, sample size distributions, stopping probabilities, and estimates of treatment eﬀect that
occur on the boundaries, allowing for the comparison of potential group sequential stopping rules.
In order to fully address the scientiﬁc question posed by a trial it is generally preferred to present stopping
boundaries based upon a statistic which represents some clinically meaningful measure of treatment eﬃcacy.
This logic no longer holds when using a nonparametric test statistic such as a weighted logrank statistic
since one is no longer testing a speciﬁc parameter of interest. Hence care must be taken when considering
potential stopping rules in order to examine what point estimates for clinically meaningful measures arise
upon study termination. Although we have demonstrated our methods in a hypothetical setting, the approach
described here was one used in the planning of a Phase III study designed to investigate the eﬃcacy of an
experimental treatment for lung cancer. Of great interest to the investigators were the tradeoﬀs between
eﬃciency (as measured by average sample sizes) and loss of power (in the absence of increasing sample size
to accommodate interim analyses), as well as the potential magnitude of the treatment eﬀect corresponding
to statistically signiﬁcant results. Through the presented case studies we demonstrated that contradictions
between decisions based upon particular weighted logrank statistics and clinically meaningful measures of
treatment eﬀect can frequently arise. In particular, it was demonstrated that in cases where our test statistic
rejected in favor of eﬃcacy, commonly used measures of treatment eﬀect were sometimes found to indicate
harm. Similar contradictions were found when decisions in favor of futility were made. This potential
for contradiction can have bearing on the functioning of the data safety monitoring committee, regulatory
agencies, and the eventual marketing of a new treatment. Careful evaluation of the design is therefore crucial
to ensure that everyone understand and agree upon the appropriateness of a stopping rule selected for a
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particular study.
When evaluating designs in the setting of nonproportional hazards, we have not extended the methods
of Emerson et al. (2004a), Emerson et al. (2004b), and Emerson et al. (2004c) for describing inference and
futility measures. The presentation of frequentist conﬁdence intervals and Bayesian posterior probabilities
and credible intervals is made quite diﬃcult due to the lack of a single parameter measuring treatment
eﬀect. We note that futility measures such as conditional power could be estimated in this setting, but are
computationally quite complicated when using simulations because conditioning on interim results requires
a prohibitively large number of simulations. Further, Gillen and Emerson (2005) compare the choice of
orderings of the sample space with respect to the calculation of corrected P -values under nonproportional
hazards. They show that the Z-statistic ordering (Chang, 1989) consistently results in lower P -values relative
to the analysis time ordering (Tsiatis et al., 1984) under late occurring treatment eﬀects.
Although the evaluation techniques proposed here are based on simulation and can be time intensive, they
are relatively straightforward in nature and do provide reasonable estimates of the operating characteristics
generally considered when evaluating potential designs. Thus, given the importance of a priori planning for
large scale clinical trials, this investment in time should be deemed negligible.
The research was supported in part by grant # HL69719 from the National Heart, Lung, and Blood
Institute.
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